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Background: For accurate estimation of the future burden of communicable diseases, the dynamics of the
population at risk – namely population growth and population ageing – need to be taken into account. Accurate
burden estimates are necessary for informing policy-makers regarding the planning of vaccination and other
control, intervention, and prevention measures. Our aim was to qualitatively explore the impact of population
ageing on the estimated future burden of seasonal influenza and hepatitis B virus (HBV) infection in the
Netherlands, in the period 2000–2030.
Methods: Population-level disease burden was quantified using the disability-adjusted life years (DALY) measure
applied to all health outcomes following acute infection. We used national notification data, pre-defined disease
progression models, and a simple model of demographic dynamics to investigate the impact of population ageing
on the burden of seasonal influenza and HBV. Scenario analyses were conducted to explore the potential impact of
intervention-associated changes in incidence rates.
Results: Including population dynamics resulted in increasing burden over the study period for influenza, whereas
a relatively stable future burden was predicted for HBV. For influenza, the increase in DALYs was localised within
YLL for the oldest age-groups (55 and older), and for HBV the effect of longer life expectancy in the future was
offset by a reduction in incidence in the age-groups most at risk of infection. For both infections, the predicted
disease burden was greater than if a static demography was assumed: 1.0 (in 2000) to 2.3-fold (in 2030) higher
DALYs for influenza; 1.3 (in 2000) to 1.5-fold (in 2030) higher for HBV.
Conclusions: There are clear, but diverging effects of an ageing population on the estimated disease burden of
influenza and HBV in the Netherlands. Replacing static assumptions with a dynamic demographic approach appears
essential for deriving realistic burden estimates for informing health policy.
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Advances in medical science and improvements in nutri-
tion, housing, sanitation and other hygenic conditions
have contributed towards reducing mortality rates in the
Netherlands and globally, with the result of prolonging
the average length of life. Life expectancy (LE) in the
Netherlands has increased over the period 1950–2010
from 70.3 to 78.8 years for men, and from 72.6 to
82.8 years for women [1]. This rising trend in LE, in
combination with fertility rates continuing at replace-
ment level or slightly higher, is predicted to increasingly
skew the age distribution of the population towards older
ages. According to forecasts by Statistics Netherlands
(CBS), in 2050 there will be 4.5 million people in the
Netherlands aged 65 years and over [2] – representing
25% of the projected total population – a substantial
increase over the 15% of the total population represented
by this age category in 2008.
Demographic changes such as population ageing have
an impact on estimates of the disease burden (i.e., mor-
tality and morbidity) over time. The immune system
becomes less efficient as it ages, with the consequence
that for many infectious diseases symptoms can occur
more frequently and with greater severity in elderly
compared with younger individuals [3]. Thus, when pro-
jecting population-based disease burden into the future,
the dynamics of demographic processes such as birth,
mortality, and migration that influence the age-
distribution of the population need to be taken into
account.
We investigated the effects of two aspects of demo-
graphic change – population ageing and growth – on
the future burden of two infectious diseases in the
Netherlands. Hepatitis B (HBV) and seasonal influenza
were selected as examples because their natural histories
differ widely, especially with respect to time-scale.
Severe, life-threatening sequelae of HBV develop slowly,
often appearing many years following acute infection
[4,5], with most of the disease burden attributable to
these sequelae. Thus, HBV is a useful infection for illus-
trating the impact of increased life expectancy predicted
for the future time at which sequelae tend to appear.
The natural history of seasonal influenza and its compli-
cations operates on a much shorter time-scale than
HBV, but because both the symptomatic attack rate and
the risk of death are strongly age-dependent [6,7], the
impact of population ageing on the disease burden at-
tributable to influenza may be substantial. Furthermore,
HBV and influenza also differ with respect to the age-
groups most at risk of infection; the incidence of HBV is
highest in persons in their 30s [8], whereas influenza
mainly affects the younger population (5–14 years), with
the highest rates for complications observed in <1 years
and in 65 years and older [9].In the current study, we integrated a simple dynamic
model of demographic change with established methodology
for the computation of disease burden, to assess the im-
pact of population ageing and growth on the disease bur-
den of seasonal influenza and HBV infection in the
Netherlands over the period 2000–2030. Our goal was not
a high degree of precision, but rather we aimed to show
qualitatively the differences in estimated burden when
demographic change is taken into account.
Methods
DALY methodology
We used the pathogen-based approach for estimating
disease burden, in which the infection event serves as
the starting point, and all (future) health outcomes –
acute infection as well as short and long-term sequelae
– causally related to infection with the pathogen are
included in the total disease burden calculation [10,11].
We calculated disease burden using the disability-
adjusted life-years (DALY) measure, a concept developed
by the World Health Organization [12]. As a normative
health gap measure, DALYs quantify the difference (in
years) between an ideal health situation and the actual
health status associated with illness, disease, or injury.
One DALY corresponds to one lost year of completely
healthy life, or to multiple years lived with disability (i.e.,
experienced at less than full health). The DALY measure
is the simple sum of two components: years of life lost
(YLL) due to premature death and years of life lost due
to disability (YLD).
An advantage of the DALY methodology is that dis-
eases (both communicable and non-communicable) can
easily be compared to each other with respect to their
impact on population health. DALY calculation for the
pathogen-based disease burden approach requires a
number of sources of data: (i) an outcome tree describ-
ing disease progression through various health outcomes
with specified transition probabilities of developing each
outcome, (ii) data on the incidence of infection, disability
weights (on a scale from 0 to 1, where 0 represents perfect
health and 1 represents death) and the average duration
associated with each health outcome, and the rates of
mortality from each outcome, and (iii) life expectancy for
all ages (typically aggregated into 5-year age-groups).
Incidence data is typically retrieved from national noti-
fication or hospitalisation databases, and where neces-
sary is adjusted using multiplication factors (MFs) to
correct for under-estimation. Under-estimation can be
divided into under-ascertainment (cases at the commu-
nity level who do not seek healthcare, possibly because
infection is mild or even asymptomatic) and under-
reporting (cases who have attended healthcare services,
but who are not reported to any notification or surveil-
lance system, possibly because notification is not
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classification). YLD and YLL are computed as summa-
tions over j age groups and k health outcomes, including













where ni,a is the number of cases developing health out-
come i among age-group a, di,a and wi,a are the disability
duration and disability weight for outcome i among age
group a, mi,a is the number of deaths occurring in health
outcome i among age group a, and LEa is the life
expectancy for age-group a at time t+di,a.
DALYs were estimated for acute infections occurring
during the period 2000–2030, and 95% confidence inter-
vals were constructed around DALYs using Latin hyper-
cube sampling methods [13]. All computations and
dynamic modelling were carried out using R statistical
software [14].
Modelling demographic dynamics
Dynamic modelling of the Netherlands population was
undertaken also with the year 2000 as a starting point,
using demographic information publicly available from
CBS for that year (population size according to sex and
1-year age-group (from 0 to 85+ years), age- and sex-
specific mortality rates [1], age-specific fertility rates,
and age-specific net migration rates [15]). Life expectancy
for each age-group was then calculated from mortality
rates using standard life-table methods. Evolution of the
size and age distribution of the population over the simu-
lation period was computed using Leslie matrices [16],
and simple assumptions were implemented with respect
to temporal trends in fertility rates (an 0.08% annual
increase in fertility rate was assumed for women >27 years)
and mortality rates (annual decrease of 1.7% (males) and
1.3% (females), with larger decreases in the oldest age
groups). Sex- and age-specific net migration rates were
fixed as the average net migration over the period
2000–2009. These modelling assumptions resulted in
comparable population sizes and age distributions to




The outcome tree for HBV disease progression was
adopted from that developed as part of the Burden of
Communicable Diseases in Europe (BCoDE) project [10].
This model specifies five health outcomes potentiallyleading from acute infection: fulminant liver failure,
chronic hepatitis, compensated cirrhosis, decompensated
cirrhosis, and hepatocellular carcinoma (HCC) (Additional
file 1: Figure S1). Transition probabilities, disability weights
and durations, and MFs to correct for under-estimation
of incident cases were adapted from those compiled for
the BCoDE project (see Additional file 1: Table S1 for
details).
Acute HBV cases in the Netherlands have been notifi-
able since 1976 and are openly available; data on age,
sex, transmission route, and country of birth are
included. In the period 2000–2010 for example, the ma-
jority of acute HBV notifications occurred in males
(76.3%), and in the 35–39 years age group (15.1%; mean
of 38 notified cases per year). Notification counts were
first adjusted to account for the under-estimation of the
incidence of acute infection when using notification data
(range: 2.4–3.0) [17-19]. A second MF was applied to
correct for asymptomatic cases not attending health care
services (MF: 4.6) [18]. We then calculated mean age-
and sex-specific incidence over the period 2000 through
2010, and assumed as a default scenario that incidence
rates remained constant over the simulation period
(i.e., fixed at the average incidence rate over the period
2000–2010). The age- and sex-aggregated mean corrected
incidence rate was 1.9 per 10,000 persons (range: 1.4–2.5).
The stratified corrected incidence rates used are provided
in Additional file 1: Table S3.
Disease burden, in DALYs per year, was then com-
puted (Eqs. 1a and 1b above) taking into consideration
the evolving population age-structure and life expectancy
and dynamically calculated incidence. To isolate the effect
of demographic change on future disease burden, DALYs
were also computed using a ‘static’ demographic model
in which the age distribution, population size, and life
expectancy were assumed to remain constant throughout
the simulation period.
Scenario analyses examined the effect of decreasing in-
cidence rates over the period 2012–2030 (crudely simu-
lating the effects of increasing coverage of HBV
vaccination in all age-groups) by 2% per year, and the ef-
fect of decreasing incidence rates in the youngest age-
groups only (<15 years) of 5% per year (simulating
decreases in transmission attributable to age-targetted
vaccination [20]).
Seasonal influenza
The outcome tree for seasonal influenza and most
parameter values were also taken from the BCoDE pro-
ject and earlier work [10,11,21]. The disease progression
model specifies three long-term health outcomes leading
from acute infection: permanent disability from Acute
Respiratory Distress Syndrome, otitis media, or sepsis
(Additional file 1: Figure S2). The highest attack rate is
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tality observed in the elderly [6,7].
We calculated age-specific incidence rates from Dutch
sentinel GP consultation rates (data were obtained from
the Netherlands Institute for Health Services Research
(NIVEL)) for ILI averaged over the period 2000–2010
[22], combined with an estimate of the proportion of ILI
cases that were seropositive for influenza (32.2%) [23].
Rates were corrected for under-ascertainment of symp-
tomatic infection (i.e., not going to a GP) using a MF
range of 1.96–2.27; this was derived from two studies on
the incidence of seasonal influenza [24,25]. The age-
aggregated mean corrected incidence rate was 10.9 per
1000 persons (range: 4.9-19.0); the age-stratified corrected
incidence rates are given in Additional file 1: Table S3.
The rate of GP consultations due to influenza in the
UK (period 1991–1996) has been reported to be 9.9/
1000 person-years in the 65+ years age group, 16.4/1000
in the 15–64 years age group, and 12.2/1000 in those
aged <15 years [26]. A Dutch study conducted for
the period 2002 through 2008 [27] reported average
GP consultation rates for influenza-like-illness (ILI) of
19.7 consultations per 1000 children aged 0–4 years
(via modelling, the authors attribute 9.3/1000 to infec-
tion with the influenza virus), and a rate of 9.7/1000
in 5–15 year olds (attributing 6.3/1000 to influenza).
A recent study indicated that the incidence of ILI in the
Netherlands is decreasing over time [28].
Over 90% of influenza-related mortality occurs in
adults aged 65 years or older [29]. Age-specific mortality
rates were taken from a recent Dutch study on
influenza-associated mortality [30], which were available
for the broad age-groups 0–4, 5–24, 25–44, 45–64, 65–74,
and 75+ years. These were converted to case-fatality rates
using the corrected age-specific incidence rates derived
from ILI data. We computed the disease burden asso-
ciated with influenza in the presence of population growth
and ageing, as done for HBV. For comparison, DALYs
were also estimated using a ‘static’ demographic model
(i.e., population size, age distribution, and life expectancy
were held constant throughout the simulation period).
Influenza vaccine uptake in persons aged 60 years or
older has been approximately 75% since 2008 [31]. In
order to investigate the potential consequences of more
(or less) effective age-targetted vaccination in the future,
a scenario analysis was conducted assuming annual
decreases in incidence rates in the oldest age groups (60+




Figure 1 shows the predicted evolution of the population
age distribution as a result of the modelled changes inage-specific mortality and fertility rates over the period
2000–2030. Population ageing is illustrated by a steady
increase over time in the proportion of the population in
the age groups 55–74 years and 75 years or older, with a
corresponding decrease in the proportions for the age-
groups under 55 years.
Hepatitis B
The annual disease burden of HBV in the Netherlands
(in DALYs, split into YLD and YLL per year) predicted
using the dynamic model is shown in Figure 2. The
overall burden increased slightly over the simulation
period, from 1196 DALYs (95% CI: 1003–1328; 413 YLL,
95% CI: 352–486) in the year 2000 to 1343 DALYs (95%
CI: 1194–1493; 561 YLLs, 95% CI: 483–650) in 2030.
Considering infection in the year 2000 only, in males the
greatest disease burden of 136 DALYs occurred in
the age group with the highest incidence (reflecting
the largest number of susceptibles and the highest risk
of infection: 30–34 years) (Figure 3), but a relatively
high burden is also apparent for the 20–24 years age
group, mainly due to high YLL (116 DALYs for males,
86 DALYs for females). Of all age groups, persons aged
20–24 years at infection had the highest YLL, 104,
attributable to relatively high incidence and an increased
probability of developing severe sequelae at middle age.
Consistent with the natural history of HBV-related dis-
ease, the majority of the burden is comprised of YLD
until approximately 45 years following infection, after
which the proportion of YLL increases (Figure 4).
Compared with results using a ‘static’ demographic
model, in which the population size, age distribution,
and life expectancy were held constant, the dynamic
model predicted an overall increased burden, ranging
from 1.34-fold higher burden in 2000 through a 1.50-
fold higher burden in 2030. This greater burden for the
dynamic model was largely represented by persons aged
15–39 years at infection (Figure 5).
The scenario analysis indicated a decrease of 32% in
the expected DALYs in 2030 if the incidence rate
decreased by 2% per year in all age groups from 2012,
compared with the constant incidence rate assumption
(Figure 6). In the scenario simulating an annual 5% de-
crease from 2012 in incidence rates in children under
15 years old, the expected total DALYs were 97% of that
for the baseline scenario. Approximately 16 acute infec-
tions in 2030 were prevented in this scenario.
Influenza
Figure 7 shows the annual disease burden of seasonal in-
fluenza. Assuming unchanging incidence rates over time,
the total estimated burden increased from 22,712 DALYs
(95% CI: 21,132–24,290) associated with infection in
2000, to 51,609 (95% CI: 48,212–55,198) in 2030. The
Figure 1 Simulated change in the age distribution of the Netherlands population over the period 2000 to 2030 (left panel) and the
corresponding change in the size of each age-group over the same period (right panel).
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90.8% to 95.5% across the same time period. There was
an increased burden in persons aged 55 or older, with
the largest increases predicted for the oldest age groups
(75 years and older); the effect of population ageing was
also more apparent in females than in males (Figure 8).
This increased burden in persons aged 55 and older sim-
ultaneously reflects a growing denominator (more
elderly people in future) and increasing LE over time
(DALYs per infected case in persons 75 years and older
increased from 1.08 in 2000 to 1.47 in 2030). The bur-
den for persons aged 25–54 years dropped over the
simulation period, following the expected proportional
decrease in the size of this age group.
Compared with a ‘static’ population model (with con-
stant population size, age distribution, and life expectancyFigure 2 The modelled annual disease burden of HBV in the Netherla
period 2000–2030. Vertical lines indicate 95% confidence intervals.across the simulation period), the model incorporating
demographic dynamics resulted in a total disease burden
varying between 1.00-fold (in 2000) and 2.27-fold (in
2030) higher.
The scenario analysis investigating the consequences of
decreasing trends in incidence rates for the 60+ years age
group from 2012 indicated substantial reductions in the
overall disease burden, mainly in YLL, were achieved
with moderate reductions in the incidence of infection
(Figure 9). For the scenarios assuming 2% and 5% decreas-
ing incidence rate trends, the expected total DALYs for
influenza infection in 2030 were 77% and 55%, respectively,
of the expected total DALYs in the baseline scenario of
constant incidence rates. If incidence rates in this age
group increased at 2% per year, then the expected total
DALYs in 2030 were 134% that of the baseline scenario.nds (split into YLD and YLL per year), for acute infections in the
Figure 3 Age-group specific estimated burden of HBV, comparing acute infections occurring in the years 2000 and 2030, plotted
separately for males (upper) and females (lower). Vertical lines indicate 95% confidence intervals.
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By simulating the ageing and growth of the Dutch popu-
lation over the period 2000 through 2030, we found di-
verging trends in the future disease burden associated
with infection with acute HBV and seasonal influenza.
For both infections considered, incorporation of a simple
model of population growth and ageing predicted a
higher overall disease burden for both infections than if
population size, age distribution, and life expectancy
were assumed to remain constant over time (the steady-Figure 4 Estimated HBV burden as a function of time since infection,state assumption). For HBV, this greater disease burden
is mainly attributable to the increased life expectancy at
the time sequelae develop; note that this effect is larger
for HBV (total DALYs for persons infected in 2000 were
1.3 times higher; Figure 5) compared with influenza. The
difference is in part due to the very different time-scales
of progression to sequelae of the two diseases. For influ-
enza, the effect of population ageing is more pro-
nounced for infection occurring in the future, when
the elderly segment of the population – for which bothfor acute infections occurring in the year 2000 only.
Figure 5 Comparison of dynamic with static modelling assumptions with respect to population growth and ageing on the annual
burden of HBV in the Netherlands (in DALYs per year), for acute infections occurring in the year 2000 and aggregated across sex.
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increased. DALYs were estimated at 2.3 times higher
than predicted by the static model for infection with in-
fluenza in the year 2030.
For HBV, population ageing also meant that the rela-
tive size of the population in the age group most at risk
for acute infection diminished over the simulation
period, giving rise to fewer incident infections overall
and a lower projected future burden. At the same time,
the increase in life expectancy over the simulation
period predicts an increase in the opportunity to develop
long-term sequelae, and for those persons who die from
HBV-related severe sequelae, the YLL component of the
disease burden will also increase (Figure 2). These two
opposing influences on the burden resulted in a rela-
tively stable trend in DALYs over the simulation period.
In contrast, for seasonal influenza our results indicated
an overall increasing burden over the simulation period.
The effect of population ageing is mostly attributable to
the growing size of the elderly population. This effect isFigure 6 HBV burden estimates in three scenarios: age-specific incide
2% per year from 2012 (corresponding to increasing vaccination rate
year in the under-15 years age-groups only (reflecting the effect of alocalised in YLL, due to increased life expectancy over
time and the highest mortality rates occurring in the
oldest age groups. The effect of population ageing on
disease burden was more pronounced for the female
than the male elderly, due to longer female life
expectancy.
We note that our estimated influenza burden is much
higher than previously reported for seasonal influenza
[11] or for the 2009 H1N1 pandemic [21]. These previ-
ous studies computed DALYs based on reported influenza
mortality, whereas we incorporated modelled mortality
rates [30] to avoid underestimation due to limited labora-
tory confirmation or influenza not being reported as the
primary cause of death.
The evolution of the age distribution in the population
is entirely driven by the demographic processes of mor-
tality, fertility, and migration. We have not attempted to
closely fit population-level data on temporal trends in
these rates; our goal was to show the impact on disease
burden from a typical ageing population that is thence rates are constant over time; decreasing incidence rates of
s in all age groups); and decreased incidence rates of 5% per
ge-targetted vaccination).
Figure 7 The modelled annual disease burden of seasonal influenza in the Netherlands (split into YLD and YLL per year), for acute
infections occurring in the period 2000–2030. Vertical lines indicate 95% confidence intervals.
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accurate model fit.
Previous research has used models of transmission dy-
namics to predict the effects of demographic change
(population decline and ageing) on the incidence of
childhood disease [32,33]. Other work has employed
projections for cause-specific mortality rates and popula-
tion growth/ageing to estimate the future global burden
of disease (e.g., the burden in 2030 based on WHO 2002
estimates) in terms of DALYs [34], but has not specifically
examined the impact of population ageing. Using a simple
extrapolation method, a Dutch study estimated the
relative change in the burden attributable to nine
infectious agents in 2050, based on prevalence/incidenceFigure 8 Age-group specific estimated burden of seasonal influenza,
plotted separately for males (upper) and females (lower). Vertical linesin 2008 and projections for the population age-group dis-
tribution [35]. Our study is the first to investigate the
effects of ageing on disease burden using the DALY
methodology and realistic models of disease progression.
One limitation of the current study is that we have
assumed that the parameters underlying transmission
dynamics do not change over time; incidence rates
reflect the force of infection (determined by contact pat-
terns between age/risk groups and the prevalence of acute
infection in the population), and interventions such as vac-
cination will influence future incidence. In addition, demo-
graphic changes such as population growth and ageing can
influence the transmission of infection through shifts in the
size of the subpopulations that are susceptible to infection.comparing acute infections occurring in the years 2000 and 2030,
indicate 95% confidence intervals.
Figure 9 Influenza burden estimates in four scenarios for trends in incidence rates from 2012, for the 60+ years age group only
(upper) and for all ages combined (lower). In each scenario, the affected incidence rates for the 60+ age group were (i) constant, (ii)
decreased by 2% per year from 2012, (iii) decreased by 5% per year, and (iv) increased by 2% per year.
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transmission dynamics remain constant, localising any
trends in disease burden to population dynamics only.
A second limitation concerns data quality, namely the
assumptions underlying the estimation of annual inci-
dence. For HBV, a single MF was applied over the entire
simulation period to account for under-estimation inher-
ent in the notification data, namely under-reporting and
under-ascertainment of cases. For influenza, the MF
range was based on two studies only (conducted in
Hong Kong in 2008 and Scotland in 1993–1994); thus,
generalisability to the Netherlands setting is an issue.
The accuracy of the calculated DALYs depends strongly
on the accuracy of the reconstructed incidence of acute
infection, and thus also on the MFs.
For HBV we have not considered the influence of
acute infection in first-generation migrants (FGMs) from
endemic countries, or secondary transmission from
FGMs. Based on serological survey data from 2007, it is
estimated that 1.4% of FGMs in the Netherlands are
chronically infected, representing 51% of the infected
population [36]. Screening and treatment of this high-risk
group has been shown to be cost-effective in preventing
future HBV-related burden [37]. As a consequence of
improved screening/treatment of FGMs from high-prevalence countries, higher vaccination coverage of their
children, and/or prevention initiatives in the countries of
origin, the incidence rate for acute infection may decrease
over time, reducing the anticipated future disease burden.
Furthermore, for HBV we have simplified certain
parameters; e.g., we assumed the disability durations for
compensated cirrhosis and HCC to be equivalent for
males and females and constant for all ages. For influenza,
age-specific disability weights for the long-term sequela of
otitis media were simplified to a single value.
Finally, the pathogen-based approach attributes all future
burden arising from initial infection to the year of infec-
tion. Figure 4 indicates the temporal aspects of the HBV
disease burden, by projecting disease progression over
time; it can be seen for acute infections in 2000, a step in-
crease approximately 45 years after infection is apparent,
with the majority burden component changing from YLD
to YLL. Such information on the temporal variation in the
burden of diseases with long natural histories may be use-
ful for the strategic planning of adequate medical care and
the provision of timely intervention measures.
Conclusions
The ageing of the population is expected to have a clear
impact on the future disease burden of HBV and
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using steady-state assumptions is not realistic. We em-
phasise that our results should not be interpreted as
forecasts, but rather as a qualitative investigation into
the effects of population change. As such, results are
generalisable to other countries with similar demo-
graphic dynamics and age-specific patterns in incidence.
Future work is required to refine these findings; for
instance, by incorporating the time-dependent effects of
potential public health interventions, changes in contact
patterns, risk factors, or, in the case of HBV, the number
of chronic carriers entering the population [36], as well
as evolutionary changes in the pathogen; all can influ-
ence transmission, and thus the incidence of infection
and future burden of disease.
Additional file
Additional file 1: Outcome trees and parameter values for hepatitis
B and influenza.
Abbreviations
BCoDE: Burden of Communicable Diseases in Europe; CI: Confidence interval;
CBS: Statistics Netherlands; DALY: Disability-adjusted life-years; HBV: Hepatitis
B virus; MF: Multiplication factor; ILI: Influenza-like illness; YLD: Years of life
lost due to disability; YLL: Years of life lost.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SM conceptualised the study, carried out the simulations and burden
computations, and drafted the manuscript. MK conceptualised the study,
advised on modelling, interpreted the results, and edited the manuscript.
AvL and DP interpreted the results and edited the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This research was partly funded by the European Centre for Disease
Prevention and Control (Specific agreement No 1 to Framework Partnership
Agreement GRANT/2008/003). We would like to thank Jan Gravestein and Gé
Donker at NIVEL, Femke Koedijk and Kees van den Wijngaard at RIVM, and
Alessandro Cassini, Edoardo Colzani, and Piotr Kramarz of the European
Centre for Disease Prevention and Control and the members of the BCoDE
consortium.
Author details
1Centre for Infectious Disease Control, National Institute for Public Health
and the Environment, PO Box 1, Bilthoven, 3720 BA, the Netherlands.
2Department of Public Health Medicine, School of Public Health, University
of Bielefeld, Bielefeld, Germany. 3Julius Centre for Health Sciences & Primary
Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
Received: 15 May 2012 Accepted: 23 November 2012
Published: 5 December 2012
References
1. Statistics Netherlands (CBS): Life expectancy; sex and age, from 1950
[Levensverwachting; geslacht en leeftijd, vanaf 1950]. Voorburg, NL: CBS; 2011.
http://statline.cbs.nl/.
2. Statistics Netherlands (CBS): Life expectancy according to sex, 2005–2050
[Levensverwachting naar geslacht, 2008–2050]. Voorburg, NL: CBS; 2008.
http://statline.cbs.nl/.
3. Liang SY, Mackowiak PA: Infections in the elderly. Clin Geriatr Med 2007,
23(2):441–456. viii.4. Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis
2003, 23(1):47–58.
5. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45(2):507–539.
6. Simonsen L: The global impact of influenza on morbidity and mortality.
Vaccine 1999, 17(Suppl 1):S3–S10.
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ,
Fukuda K: Mortality associated with influenza and respiratory syncytial
virus in the United States. JAMA 2003, 289(2):179–186.
8. Centers for Disease Control and Prevention: Viral hepatitis surveillance. USA:
2011. http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm.
9. Rothberg MB, Haessler SD, Brown RB: Complications of viral influenza.
Am J Med 2008, 121(4):258–264.
10. Kretzschmar ME, Mangen M-J, Pinheiro P, Jahn B, Fèvre EM, Longhi S, Lai T,
Havelaar AH, Stein C, Cassini A, et al: New methodology for estimating
the burden of communicable diseases in Europe. PLoS Med 2012,
9(4):e1001205.
11. van Lier EA, Havelaar AH, Nanda A: The burden of infectious diseases in
Europe: a pilot study. Euro Surveill 2007, 12(12):E3–E4.
12. Murray CJL, Lopez AD: The Global Burden of Disease: a comprehensive
assessment of mortality and disability from diseases, injuries, and risk factors in
1990 and projected to 2020 (Global burden of disease and injuries series I).
Cambridge: Harvard School of Public Health on behalf of the World Health
Organization and the World Bank; 1996.
13. McKay M, Beckman R, Conover WA: Comparison of three methods for
selecting values of input variables in the analysis of output from a
computer code. Technometrics 1979, 21(2):239–245.
14. R Development Core Team: R: A Language and Environment for Statistical
Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
15. Statistics Netherlands (CBS): Immigration and emigration according to
country of birth and age (31 December) and sex [Immi- en emigratie naar
geboorteland, leeftijd (31 december) en geslacht]. Voorburg, NL: CBS; 2011.
http://statline.cbs.nl/.
16. Leslie PH: The use of matrices in certain population mathematics.
Biometrika 1945, 33(3):183–212.
17. Alter MJ, Mares A, Hadler SC, Maynard JE: The effect of underreporting on
the apparent incidence and epidemiology of acute viral hepatitis. Am J
Epidemiol 1987, 125(1):133–139.
18. Ramsay ME, Balogun MA, Collins M, Balraj V: Laboratory surveillance of
hepatitis C virus infection in England and Wales: 1992 to 1996. Commun
Dis Public Health 1998, 1(2):89–94.
19. World Health Organisation (WHO): Introduction of Hepatitis B vaccine into
childhood immunization services. Management guidelines, including
information for health workers and parents. Geneva: WHO; 2001.
20. Health Council of the Netherlands: General vaccination against hepatitis B
revisited. The Hague: Health Council of the Netherlands; 2009.
21. Wielders CC, van Lier EA, van ’t Klooster TM, van Gageldonk-Lafeber AB,
van den Wijngaard CC, Haagsma JA, Donker GA, Meijer A, van der Hoek W,
Lugner AK, et al: The burden of 2009 pandemic influenza A(H1N1) in the
Netherlands. Eur J Public Health 2012, 22(1):150–157.
22. Donker GA: Continuous Morbidity Registration Sentinel Stations the
Netherlands 2010. Utrecht: Nivel; 2011.
23. Dijkstra F, van Gageldonk-Lafeber AB, van Brandsema PR, du Beest Holle M,
Meijer A, van der Lubben IM, Wilbrink B, van der Sande MAB: Annual
respiratory diseases report 2005/2006. [Jaarrapportage respiratoire
infectieziekten 2005/2006]. Bilthoven: RIVM; 2006.
24. Elder AG, O’Donnell B, McCruden EA, Symington IS, Carman WF: Incidence
and recall of influenza in a cohort of Glasgow healthcare workers
during the 1993–4 epidemic: results of serum testing and questionnaire.
BMJ 1996, 313(7067):1241–1242.
25. Lau LL, Cowling BJ, Fang VJ, Chan KH, Lau EH, Lipsitch M, Cheng CK,
Houck PM, Uyeki TM, Peiris JS, et al: Viral shedding and clinical illness
in naturally acquired influenza virus infections. J Infect Dis 2010,
201(10):1509–1516.
26. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H: Population-based
study on incidence, risk factors, clinical complications and drug
utilisation associated with influenza in the United Kingdom. Eur J Clin
Microbiol Infect Dis 2000, 19(11):834–842.
27. Paget WJ, Balderston C, Casas I, Donker G, Edelman L, Fleming D, Larrauri A,
Meijer A, Puzelli S, Rizzo C, et al: Assessing the burden of paediatric
influenza in Europe: the European Paediatric Influenza Analysis (EPIA)
project. Eur J Pediatr 2010, 169(8):997–1008.
McDonald et al. BMC Public Health 2012, 12:1046 Page 11 of 11
http://www.biomedcentral.com/1471-2458/12/104628. Dijkstra F, Donker GA, Wilbrink B, Van Gageldonk-Lafeber AB,
Van Der Sande MA: Long time trends in influenza-like illness and
associated determinants in The Netherlands. Epidemiol Infect 2009,
137(4):473–479.
29. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K:
Pandemic versus epidemic influenza mortality: a pattern of changing
age distribution. J Infect Dis 1998, 178(1):53–60.
30. van den Wijngaard CC, van Asten L, Koopmans MP, van Pelt W,
Nagelkerke NJ, Wielders CC, van Lier A, van der Hoek W, Meijer A,
Donker GA, et al: Comparing pandemic to seasonal influenza mortality:
moderate impact overall but high mortality in young children. PLoS One
2012, 7(2):e31197.
31. Jansen B, Tacken M, Mulder J, Visscher S, Tiersma W, Braspenning J:
Monitoring vaccination rates: Dutch national influenza prevention programme
2010 [Monitoring vaccinatiegraad: Nationaal Programma Grieppreventie 2010].
Nijmegen: LINH; 2011.
32. Manfredi P, Williams JR: Realistic population dynamics in epidemiological
models: the impact of population decline on the dynamics of childhood
infectious diseases. Measles in Italy as an example. Math Biosci 2004,
192(2):153–175.
33. Williams JR, Manfredi P: Ageing populations and childhood infections: the
potential impact on epidemic patterns and morbidity. Int J Epidemiol
2004, 33(3):566–572.
34. Mathers CD, Loncar D: Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 2006, 3(11):e442.
35. Bijkerk P, van Lier EA, van Vliet JA, Kretzschmar ME: Effecten van vergrijzing
op infectieziekten. Ned Tijdschr Geneeskd 2010, 154:A1613.
36. Hahne SJ, de Melker HE, Kretzschmar M, Mollema L, van der Klis FR, van der
Sande MA, Boot HJ: Prevalence of hepatitis B virus infection in The
Netherlands in 1996 and 2007. Epidemiol Infect 2011, 140(8):1469–1480.
37. Veldhuijzen IK, Toy M, Hahne SJ, De Wit GA, Schalm SW, de Man RA,
Richardus JH: Screening and early treatment of migrants for chronic
hepatitis B virus infection is cost-effective. Gastroenterology 2010,
138(2):522–530.
doi:10.1186/1471-2458-12-1046
Cite this article as: McDonald et al.: The impact of demographic change
on the estimated future burden of infectious diseases: examples from
hepatitis B and seasonal influenza in the Netherlands. BMC Public Health
2012 12:1046.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
